Arcturus Story

<div class='circular--portrait' style='background:#82ADFD;color: #ffffff;font-size:4em;'>AT</div>
ARCT -- USA Stock  

USD 67.70  3.93  6.16%

In general, we focus on analyzing Arcturus (NASDAQ:ARCT) price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arcturus Therapeutics daily price indicators and compare them against related drivers. While this unique economic environment continues, Arcturus Therapeutics may throw investors more surprises before the next earnings call. We will evaluate why we are still confident in anticipation of a recovery.
Published over a month ago
View all stories for Arcturus Therapeutics | View All Stories
Will Arcturus Therapeutics investors stop to exit in December?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Arcturus Therapeutics has an asset utilization ratio of 0.48 percent. This implies that the company is making $0.00482 for each dollar of assets. An increasing asset utilization means that Arcturus Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.
The successful prediction of Arcturus Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Arcturus Therapeutics, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Arcturus Therapeutics based on Arcturus Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to Arcturus Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Arcturus Therapeutics's related companies.

Use Technical Analysis to project Arcturus expected Price

Arcturus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Arcturus Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Arcturus Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Arcturus Therapeutics, but it might be worth checking our own buy vs. sell analysis

Detailed Outlook On Arcturus Therapeutics

The newest price gain of Arcturus Therapeutics could raise concerns from private investors as the firm it trading at a share price of 76.00 on very low momentum in volume. The company management teams may have good odds in positioning the firm resources to exploit market volatility in December. The stock standard deviation of daily returns for 30 days investing horizon is currently 8.74. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Arcturus Therapeutics partners.

Deferred Revenue Breakdown

Arcturus Therapeutics Deferred Revenue yearly trend continues to be comparatively stable with very little volatility. Deferred Revenue will likely drop to about 20.9 M in 2020. Deferred Revenue usually refers to a component of Total Liabilities representing the carrying amount of consideration received or receivable on potential earnings that were not recognized as revenue; including sales; license fees; and royalties; but excluding interest income. Arcturus Therapeutics Deferred Revenue is comparatively stable at the moment as compared to the past year. Arcturus Therapeutics reported Deferred Revenue of 23.58 Million in 2019
20107.59 Million
201713.65 Million
201813.81 Million
201923.58 Million
202020.9 Million

Our take on today Arcturus Therapeutics gain

The mean deviation is down to 5.16 as of today. Arcturus Therapeutics is showing large volatility of returns over the selected time horizon. We encourage all investors to investigate this asset further to make sure related market timing strategies are aligned with all the expectations about Arcturus Therapeutics implied risk.

Our Final Take On Arcturus Therapeutics

Whereas some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Arcturus Therapeutics may offer a potential longer-term growth to private investors. To conclude, as of the 28th of November 2020, our final 30 days Buy-Hold-Sell recommendation on the firm is Hold. We believe Arcturus Therapeutics is overvalued with very low odds of financial turmoil for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Arcturus Therapeutics. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to